Online inquiry

IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ11706MR)

This product GTTS-WQ11706MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Humanized
RefSeq	NM_001354991.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3596
UniProt ID	P35225

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11706MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ13753MR	IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	REGN 1500
GTTS-WQ8424MR	IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	HSP90mab
GTTS-WQ10951MR	IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	MBG-453
GTTS-WQ8567MR	IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	Hu5F9-G4
GTTS-WQ6098MR	IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	CNTO-1959
GTTS-WQ2888MR	IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	AMG-761
GTTS-WQ11418MR	IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	MEDI-8897
GTTS-WQ1694MR	IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	aDabi-Fab

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST